Get started
Work

2395P Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC)

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.09.1044
Authors: A. Sood, J.M. Jacob, G. Bratslavsky, P. Grivas, P. Spiess, R. Li, A. Necchi, J. Posada, E. Yakirevich, L. Cheng, D.C. Pavlick, R. Huang, D.I. Lin, N.A. Danziger, E.S. Sokol, S. Sivakumar, J.S. Ross, A. Kamat
Institutions: The University of Texas MD Anderson Cancer Center, SUNY Upstate Medical University, University of Washington, Moffitt Cancer Center, IRCCS Ospedale San Raffaele, Brown University, Rhode Island Hospital, Lifespan, Foundation Medicine (United States)
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
Funders: Prostate Cancer Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, American Society of Clinical Oncology, Celgene, Regeneron Pharmaceuticals, Merck KGaA, Exelixis, Clovis Oncology, Mirati Therapeutics, Incyte, Calithera Biosciences, Cardinal Health, Silverback Therapeutics, Moderna, UroGen Pharma, G1 Therapeutics, Seagen, Eisai, Astellas Pharma, European Society for Medical Oncology, Bavarian Nordic, Genentech, EMD Serono, Loxo Oncology, Janssen Biotech
OpenAlex ID: W4387826786
FWCI:
Cites:
Cited by:
Related to: 10